Low versus high peripheral oxygen saturation directed oxygen therapy in critically ill patients: a multicenter randomized controlled trial
Xiaobo Yang , Xuehui Gao , Xiang Zheng , Xu Zhao , Yanli Liu , Lu Zhang , Junli Sun , Peng Wang , Zhengqin Xu , Ronghua Hu , Hongbin Li , Hong Qi , Yin Yuan , Wei Chen , Jie Liu , Guangqing Huang , Li Yu , Fengsheng Cao , Keke Xin , Min Yu , Xiaoyun Liu , Li Zhang , Siyuan Chang , Xiaojing Zou , Hong Liu , Zhaohui Fu , Huaqing Shu , Yuan Yu , Jiqian Xu , Shiying Yuan , You Shang
MedComm ›› 2025, Vol. 6 ›› Issue (3) : e70098
Low versus high peripheral oxygen saturation directed oxygen therapy in critically ill patients: a multicenter randomized controlled trial
Whether low peripheral oxygen saturation (SpO2) directed oxygen therapy is associated with lower mortality in critically ill patients needs further exploration. Adult critically ill patients from 11 intensive care units in China were screened. Participants were randomly assigned to the low SpO2 (90%–95%) group or the high SpO2 (≥96%) -group. The primary outcome was 28-day all-cause mortality. The secondary outcomes were hours free from ventilators and from renal replacement therapy (RRT) within 14 days. Note that 857 patients in the low SpO2 group and 849 in the high SpO2 group were included. In the low SpO2 group versus the high SpO2 group, the time-weighted average of the fraction of inspired oxygen (FiO2) was significantly lower (33.5 ± 9.7% vs. 39.6 ± 9.3%, p < 0.001), and so was the time-weighted average of SpO2 (95.9 ± 1.8% vs. 98.0 ± 1.9%, p < 0.001). Within 28 days after randomization, 172 (20.1%) in the low SpO2 group and 193 (22.7%) in the high SpO2 group died (p = 0.180). Ventilator-free time and RRT-free time were not significantly different within 14 days. In critically ill patients, low SpO2directed oxygen therapy did not decrease 28-day mortality, 14-day ventilator-free time, or 14-day RRT-free time.
mechanical ventilation / mortality / oxygen therapy / partial pressure of arterial oxygen / peripheral oxygen saturation / renal replacement therapy
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
|
| [19] |
|
| [20] |
ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group, |
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.
/
| 〈 |
|
〉 |